KY1043 / Sanofi - LARVOL DELTA

[VIRTUAL] KY1043, a novel CD25-directed PD-L1 IL-2 immunocytokine, delivers potent anti-tumor activity in vivo via an expansion of a Tcf1hi PD-1+ CD8+ T cell population (AACR-II 2020) - "In conclusion, KY1043 induces highly effective tumor killing in vivo, believed to be driven by the preferential expansion of a recently discovered ‘stem-like’ CD8+ T cell population in the tumor microenvironment. These results challenge the dogma that selective binding to the dimeric ‘βγ’ IL-2R is required for tumor control and demonstrate that a CD25-directed immunocytokine may provide an advantageous therapeutic-index for the treatment of cancer."

IO Biomarker • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CD8 • FOXP3 • IL2 • IL2RA • PD-1 • PD-L1

"#KY1043 #Kymab's anti-PD-L1 IL2 immunocytokine #AACR2020 https://t.co/b3n9UIeyKN" (@rcasainson)

Oncology • IL2

Kymab presents update on lead immunocytokine program KY1043 at Society of Immunotherapy for Cancer 34th Annual Meeting (GlobeNewswire) - “Data presented in the SITC poster demonstrate that KY1043 retains the ability to effectively inhibit PD-1/PD-L1 interaction and binds preferentially to the IL-2Ra (CD25)-containing high-affinity trimeric IL-2Rabg receptor present on antigen-experienced and activated T cells as well as on regu­latory T cells (Treg). In vitro, KY1043 increases antigen-specific T cell-mediated killing of tumor cells. In vivo, KY1043 administration produces profound tumor growth suppression in an established MC38 tumor model…Mice treated with KY1043 are resistant to subsequent tumor challenge, indicating the potential for long-term anti-tumor memory responses.”

Preclinical

KY1043, a novel PD-L1 IL-2 immunocytokine directed towards CD25, delivers potent anti-tumour activity in vitro and in vivo (SITC 2019) - "KY1043 induces potent T cell activation and can direct highly effective tumour killing in vitro and in vivo. These results challenge the dogma that selective binding to dimeric (CD122/CD132) IL-2R is required for tumour control and demonstrate that a CD25 directed immunocytokine may provide an advantageous therapeutic-index for the treatment of cancer."

Preclinical

"#Kymabltd to present a poster at #SITC19 on a new type of immunocytokine #KY1043 #immunoOncology #nextwave #Immunotherapy" (@rcasainson)